An FDA scientist at the bench in the agency's own research centre. This story is about what the agency's reviewers concluded, not about a political decision.
The U.S. Food and Drug Administration
Illustrative. An FDA National Center for Toxicological Research laboratory, not the review described here.
FDA's Own Scientists Say No to BPC 157, TB 500, and MOTS C Compounding
I've written before about how thin the human evidence is for nasal BPC 157, but this week that argument stopped being just my read of the outside literature. The FDA's own career scientists looked at the same question, and reached the same conclusion, in an official government document, right before a vote that will decide whether compounding pharmacies get to legally make it at all.
- FDA career scientists released briefing documents on June 30, 2026 recommending against adding BPC 157, TB 500, and MOTS C to the list that would let compounding pharmacies legally manufacture them.
- Their own review found zero human pharmacokinetic data for BPC 157 by nasal spray, oral capsule, or injection. The only human data anywhere comes from rectal enema studies, where the peptide wasn't even detected in blood.
- TB 500 has no human studies at all, and MOTS C has none published either.
- An advisory panel with documented industry ties votes on all seven peptides July 23 and 24, 2026, and could approve them anyway, directly against its own agency's findings.
- 0
- Human PK studies, any route people buy
- 2
- Human studies, rectal enema, not detected in blood
- 0
- Human studies of TB 500, of any kind
- 0
- Published human studies of MOTS C
A regulator says no, but the vote isn't final
On June 30, 2026, FDA staff released briefing documents on seven peptides under review for the 503A Bulks List, the list that determines what compounding pharmacies can legally manufacture. Three of those, BPC 157, TB 500, and MOTS C, got a clear recommendation against inclusion. That lands with real tension attached, since HHS Secretary RFK Jr has been publicly pushing to widen peptide access, and the advisory committee that actually votes on this, the Pharmacy Compounding Advisory Committee, includes members with documented industry ties. The vote happens July 23 and 24, 2026, and it could go against the staff's own recommendation.
What the evidence actually shows
the case against BPC 157 rests on three legs
Read directly from the memo, the case against BPC 157 rests on three legs. First, characterization: there's no official monograph for it, naming is inconsistent across suppliers, and impurity profiles aren't verified, so FDA can't confirm what's actually in the products people are buying. Second, effectiveness: there is no human pharmacokinetic data for BPC 157 by oral, injectable, nasal, or topical routes at all. The only human PK data that exists anywhere comes from two studies using rectal enemas, and in those, BPC 157 wasn't even detected in the bloodstream. Third, safety: FDA flagged insufficient clinical safety information, no long duration human studies, and a real immunogenicity risk from injecting or spraying a short chain peptide. TB 500 has zero human studies of any kind, and MOTS C has none published either.
- Characterization
- No official monograph, inconsistent naming across suppliers, unverified impurity profiles. FDA cannot confirm what is in the products people buy.
- Effectiveness
- No human pharmacokinetic data by oral, injectable, nasal or topical route at all.
- Safety
- Insufficient clinical safety information, no long duration human studies, and a real immunogenicity risk from a short chain peptide.
Honest caveat
This staff recommendation is not a final decision. The advisory committee could still vote to add these peptides to the list anyway, and several of its members have documented industry ties, which is part of the story here, not a footnote. An insufficient data conclusion is a regulatory judgment about compounding eligibility, not proof that BPC 157 doesn't work. The honest reading is unproven for these routes, not disproven.
What this means for you
If you're weighing a BPC 157 purchase, nasal spray, oral capsule, or injectable, this is about as concrete a fact as you're going to get: the FDA's own scientific staff, not a wellness blogger and not a competitor supplement brand, looked at the human safety data for the routes people are actually buying and found essentially none. That doesn't settle whether BPC 157 works. It does mean the systemic healing story being sold right now is running well ahead of the human evidence, and the July 23 and 24 vote is worth watching regardless of which way it goes.
Primary sources
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, BPC 157 (free base) and BPC 157 acetate, dated May 11, 2026, published ahead of the July 23 and 24, 2026 meeting.
- FDA Pharmacy Compounding Advisory Committee, July 23 and 24, 2026 meeting page, confirming all seven peptides under review.
- NPR, "FDA scientists flag concerns with peptides, the trendy molecules RFK Jr supports," June 30, 2026.
- NPR, "What's behind the push to make peptide therapies more readily available," July 8, 2026.
- Independently corroborated by US News, NBC News, and Becker's Hospital Review.
Common questions
What did FDA's own scientists actually find about BPC 157?
Their June 30, 2026 briefing document found no human pharmacokinetic data at all for BPC 157 taken by nasal spray, oral capsule, or injection. The only human data anywhere comes from two rectal enema studies, and in those, the peptide wasn't even detected in blood. They also flagged unverified purity and impurity profiles and no long duration human safety studies.
Does this mean BPC 157 is now illegal or proven unsafe?
No. This is a regulatory judgment about whether compounding pharmacies should be allowed to legally manufacture it, not a final scientific verdict. The honest reading is unproven for these uses and routes, not disproven. The advisory panel voting on it July 23 and 24, 2026 could still approve it despite the staff recommendation.
When will we find out if BPC 157 gets added to the compounding list?
The FDA's Pharmacy Compounding Advisory Committee votes on BPC 157 and six other peptides, including TB 500 and MOTS C, on July 23 and 24, 2026. Several committee members have documented industry ties, so the outcome is genuinely uncertain even with the staff recommendation against it.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.